Medicure Inc. (CVE:MPH – Get Free Report)’s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as C$2.61 and last traded at C$2.59, with a volume of 7300 shares traded. The stock had previously closed at C$2.59.
Medicure Price Performance
The company has a debt-to-equity ratio of 6.02, a current ratio of 0.97 and a quick ratio of 1.28. The company has a market cap of C$27.03 million, a price-to-earnings ratio of -3.60 and a beta of 0.93. The firm’s 50 day simple moving average is C$1.47 and its 200-day simple moving average is C$1.25.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
See Also
- Five stocks we like better than Medicure
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
- Chewy’s Sell-Off Puts Its Recurring Revenue Story Back on Trial for Investors
- Insider Sales Eclipse $450M Across 3 AI Winners, With NVIDIA Leading the Pack
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
